"APAC is one of the fastestgrowing photodynamic therapy markets globally"

Australia's Invion Group is emerging as a leader in the development of next generation precision photodynamic technology (PDT), known as Photosoft, for a range of cancers and other diseases. The minimally invasive treatment promises to provide a potentially more affordable option for millions of people in developed and developing markets. At the recently held BioAsia Taiwan 2025 event, which highlighted the ongoing demand for precision oncology solutions in underserved Asian markets, BioSpectrum Asia took the opportunity to interact with Thian Chew, Chief Executive Officer, Invion Group to find out more about how the company is revolutionising the oncology market with its new products and technology. Edited excerpts

- 

What are the major highlights at Invion Group in 2025? Are you planning to launch new products this year and beyond?

Photosoft is a platform technology and Invion has an active clinical pipeline, which is validating multiple applications of our lead cancer drug candidate INV043 across several indications. We now have human data on two distinct cancers – prostate cancer and non-melanoma skin cancer (NMSC). This makes our technology unique because it is unusual to see one drug showing promise on more than one type of cancer. The investigator-led Phase II prostate cancer trial in Melbourne, Australia, demonstrated a 40–44 per cent response rate and the treatment only had mild side effects and was well tolerated by participants who underwent six rounds of the treatment administered systemically.